NasdaqGM:GPCRPharmaceuticals
Structure Therapeutics’ Oral Obesity Drug Enters Phase 2 As Investor Focus Grows
Structure Therapeutics (NasdaqGM:GPCR) has advanced its lead obesity candidate GSBR-1290 into phase 2 clinical trials as an oral treatment.
The move comes as the company draws increased attention for targeting the obesity market with a pill-based approach rather than injectables.
Analyst optimism and early discussion about potential takeovers have put fresh focus on the stock.
Structure Therapeutics, trading under NasdaqGM:GPCR, is drawing fresh interest after pushing GSBR-1290 into phase...